<DOC>
	<DOCNO>NCT02470546</DOCNO>
	<brief_summary>Primary aim : -To ass effect metformin use treatment minimal hepatic encephalopathy patient liver cirrhosis . Secondary aim : -To evaluate metformin safety drug patient show liver cirrhosis .</brief_summary>
	<brief_title>Metformin Experience Minimal Hepatic Encephalopathy</brief_title>
	<detailed_description>In study , 30 patient include divided two arm . Investigators patient know treatment use ( double blind ) . Arm 1 : Metformin 1000mg twice day ( 2000 mg/day ) , 12 week . Arm 2 : Placebo 1000mg twice day ( 2000mg/day ) , 12 week . At end study , patient followed-up 8 week control appearance adverse effect .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients &gt; 18 year old Patients result factor evaluable time inclusion Patients accept participation study inform consent Patients show liver cirrhosis ultrasound , transient elastography liver biopsy Patients show minimal hepatic encephalopathy ( PHES &lt; 4 Critical Flicker Frequency &lt; 39 Hz ) Patients contraindication drug use Patients show type 1 diabetes mellitus Patients show type 2 diabetes mellitus previous current use exogenous insulin , metformin oral antidiabetic drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Hepatic encephalopathy</keyword>
	<keyword>Metformin</keyword>
	<keyword>Liver cirrhosis</keyword>
</DOC>